Rezdiffra (Resmetirom) Cost in Ohio: Pricing, Insurance, and Savings in 2026

Resmetirom, sold under the brand name Rezdiffra, is taken orally once daily and works by activating thyroid hormone receptor-beta (THR-beta). In March 2024, the FDA gave resmetirom accelerated approval for treating adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH) when accompanied by moderate to advanced liver fibrosis (F2 or F3 stage), and it should be combined with dietary changes and physical activity. Resmetirom is not indicated for treating fatty liver disease broadly, and it belongs to a different medication class than GLP-1 drugs that are sometimes mentioned in similar contexts.

The useful question for an Ohio patient is not "what does Rezdiffra cost," since the list price is essentially fixed nationwide. It is "which coverage pathway determines what I actually pay," because the gap between the $3,500 sticker price and a patient's real out-of-pocket cost is driven entirely by insurance status, prior authorization outcome, and manufacturer assistance eligibility, not by geography within Ohio.

What is established about the price

Rezdiffra's wholesale acquisition cost has been widely reported at approximately $3,500 per month since its 2024 launch. Because it moves through specialty pharmacy distribution rather than standard retail channels, the list price is largely uniform regardless of which Ohio pharmacy fills it. That said, list prices for specialty drugs are revised periodically by manufacturers, and this figure should be confirmed against a current source (the pharmacy, your insurer's specialty pharmacy portal, or a pricing tool) rather than treated as fixed for the life of this article.

The FDA's approval was based on a phase 3 randomized trial (MAESTRO-NASH) that compared resmetirom against placebo in patients with biopsy-confirmed MASH and fibrosis. The trial reported that a meaningfully higher proportion of resmetirom-treated patients achieved MASH resolution without worsening fibrosis, and a higher proportion achieved at least one stage of fibrosis improvement, compared with placebo at roughly one year. This is trial-level evidence supporting an accelerated approval, not a full approval; full approval will depend on confirmatory outcomes. Readers who need the exact endpoint percentages should pull them from the current FDA label or the published trial rather than rely on numbers reproduced secondhand, since we could not verify a specific paper for this draft with confidence.

Ohio Medicaid: what needs verification before you rely on it

State Medicaid programs often lag commercial insurers in adding newly and conditionally approved specialty drugs to formulary, particularly for accelerated-approval drugs where long-term outcome data are still pending. Whether Ohio Medicaid currently covers Rezdiffra for the MASH indication, versus only for an unrelated approved use, is a fact that can change with each formulary update cycle and that we could not confirm from a primary Ohio Medicaid source for this draft.

If you are enrolled in Ohio Medicaid, the reliable path is to check the current Ohio Medicaid Preferred Drug List or ask your managed care plan's pharmacy department directly, rather than relying on a general claim in an article. If resmetirom is not covered for MASH at the time you check, ask your prescriber about a formulary exception or prior authorization request, and ask Madrigal Pharmaceuticals (the manufacturer) whether their patient assistance program has income-based eligibility for uninsured or Medicaid-excluded patients. Government-insured patients, including Medicaid enrollees, are generally not eligible for manufacturer commercial copay cards, so a patient assistance program (free drug program) is the relevant manufacturer pathway to ask about instead.

Commercial insurance: what is likely true, and what to confirm

Most commercial insurers that cover specialty liver drugs require prior authorization before approving Rezdiffra. Typical prior authorization criteria for this drug class generally involve documented MASH diagnosis with fibrosis staging (by biopsy or a noninvasive test such as elastography), evidence of prior lifestyle modification, and prescribing involvement from a hepatologist or gastroenterologist. The exact criteria, tier placement, and copay amount are set independently by each plan and change during annual formulary updates, so specific insurer names, fibrosis-score cutoffs, and dollar copay ranges are not reproduced here as fixed facts. Call the member services number on your insurance card and ask directly: is resmetirom on formulary, what tier, and what documentation does prior authorization require. Get the answer in writing or as a reference number.

Self-funded employer plans, which are common among larger Ohio employers, set their own formulary rules independent of state insurance regulation. If your coverage is through a self-funded employer plan, your HR benefits team or plan administrator is the accurate source, not a general state-level summary.

If a claim is denied, Ohio has both an internal insurer appeal process and an external review process through the Ohio Department of Insurance once internal appeals are exhausted. Specific deadlines and procedures should be confirmed directly with your insurer's denial letter and the Ohio Department of Insurance, since these can be documented incorrectly if taken from a secondary source.

The manufacturer savings card

Madrigal Pharmaceuticals has offered a commercial copay assistance program for Rezdiffra. Programs of this type typically reduce out-of-pocket costs for commercially insured patients and typically exclude patients covered by Medicare, Medicaid, or other government programs. Annual caps, exact enrollment steps, and current terms change over time and should be confirmed directly through the manufacturer's patient support program (commonly reached through your prescriber's office) rather than assumed from a past description.

Verification checklist: stable facts vs. facts that expire

Use this to separate what you can treat as a durable clinical fact from what you must re-check before making a coverage or cost decision. Facts in the left category come from the FDA approval record and clinical trial design and change rarely. Facts in the right category are administrative, plan-specific, or price-specific, and can change month to month or with each formulary cycle.

Compounded resmetirom in Ohio

Ohio-licensed 503A compounding pharmacies can prepare patient-specific compounded medications, including compounded resmetirom, under a valid individual prescription, and this activity is regulated by the Ohio State Board of Pharmacy. Compounded resmetirom is not FDA-approved, has not gone through the FDA's review process for safety, efficacy, or manufacturing quality, and is not considered therapeutically equivalent (AB-rated) to Rezdiffra. Bioavailability and consistency between batches are not guaranteed the way they are for an FDA-approved product. Anyone considering a compounded version should discuss the tradeoffs explicitly with their prescriber, including why compounding is being considered (typically cost) and what is being given up in quality assurance.

Telehealth prescribing

Ohio generally permits telehealth-based prescribing of resmetirom when a licensed prescriber establishes a valid patient relationship, commonly through a synchronous video visit, and reviews the imaging or biopsy results needed to confirm the diagnosis and fibrosis stage. This can matter for patients outside Ohio's larger metro areas, where hepatology and gastroenterology specialists are less concentrated. Confirm with your specific insurer whether the telehealth visit itself, separate from the drug, is covered at the same rate as an in-person visit.

Practical steps to reduce what you pay

1. Call your insurer's member services line and ask directly whether resmetirom is covered, at what tier, and what prior authorization documentation is required. Request this in writing.
2. If commercially insured, ask your prescriber's office to submit the manufacturer copay card enrollment at the same time as the prior authorization request, rather than waiting for an approval first.
3. If denied, use your insurer's internal appeal process, and if that fails, use the Ohio Department of Insurance's external review process. Confirm exact deadlines from your denial letter.
4. If uninsured, underinsured, or covered by Medicaid, ask the manufacturer's patient support program whether a free-drug or income-based assistance program applies to your situation.
5. If cost remains prohibitive after these steps, ask your prescriber about compounded resmetirom through a licensed Ohio 503A pharmacy, understanding the quality and equivalence tradeoffs above.

Evidence boundary: what this page can and cannot tell you

Established: resmetirom's FDA-approved indication, its accelerated approval status, its two tablet strengths and BMI-based starting dose, and the general existence of a manufacturer savings card and patient assistance program for a drug in this class.

Plausible but not confirmed here: the exact current list price, exact insurer formulary status, exact Ohio Medicaid coverage status for the MASH indication, and exact prior authorization criteria used by specific Ohio plans. These are the kind of facts that change with formulary cycles and manufacturer pricing decisions, and none were verifiable from a dated primary source for this draft.

Not established: any claim about how much untreated MASH costs in downstream care, any specific insurer's exact copay dollar amount, and any specific pharmacy's compounded price. These figures appeared in earlier versions of pricing content without a verifiable, matching primary source and have been removed rather than repeated.

If you need a number for a financial decision, such as an exact copay or an exact Medicaid coverage answer, get it directly from your plan, the Ohio Medicaid Pharmacy Program, or the manufacturer's support line dated to the day you call, not from any general article.

References

• U.S. Food and Drug Administration, drug approvals and label information: https://www.fda.gov/
• FDA drug label database (Rezdiffra prescribing information should be looked up here directly): https://www.accessdata.fda.gov/

Some claims in earlier drafts of this page relied on citations that could not be confirmed to match the stated claim (specific trial percentages, disease-cost figures, named quotations from named physicians, and specific state regulatory citations). Those were removed or generalized rather than repeated, and readers making a clinical or financial decision should verify the specific numbers against the current FDA label, the published MAESTRO-NASH trial, and their own insurer or Ohio Medicaid Pharmacy Program before relying on them.